Cargando…
Biosimilar Insulins – What a Clinician Needs to Know?
As the first biologics produced by recombinant deoxyribonucleic acid (DNA) technology were approved in the late 1980s and consequently the exclusive marketing rights of most of these biological medicinal products have expired or will expire very shortly, it is quite evident that biosimilars are bein...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844176/ https://www.ncbi.nlm.nih.gov/pubmed/31741896 http://dx.doi.org/10.4103/ijem.IJEM_180_19 |